Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

8.250 -0.110 (-1.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 772,460
Open 8.450
Bid (Size) 8.210 (2)
Ask (Size) 9.300 (1)
Prev. Close 8.360
Today's Range 8.207 - 8.530
52wk Range 7.720 - 27.48
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace

Performance

YTD
-21.50%
-21.50%
1 Month
-22.75%
-22.75%
3 Month
-17.75%
-17.75%
6 Month
-1.55%
-1.55%
1 Year
-67.00%
-67.00%

More News

Read More
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Via Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
Recap: Vir Biotechnology Q4 Earnings
Via Benzinga
Earnings Outlook For Vir Biotechnology
Via Benzinga
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Via InvestorPlace
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
JP Morgan Downgrades Vir Biotechnology: Here's What You Need To Know
Via Benzinga
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
Via InvestorPlace
Earnings Scheduled For February 22, 2024
Via Benzinga
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
From Vir Biotechnology, Inc.
Via Business Wire
HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
Via Benzinga
Exposures COVID-19
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
Via InvestorPlace
From laggards to leaders: Small caps on the rise
Via MarketBeat
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.